Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)

Trial Profile

Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs CERC 501 (Primary)
  • Indications Depression
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RAPID KOR
  • Most Recent Events

    • 30 Jun 2017 According to a Cerecor media release, data from this trial will be presented at the American Society for Clinical Psychopharmacology Conference.
    • 01 May 2017 According to a Cerecor media release, this five-site trial was terminated early due to recruitment issues. Analysis of the data set is ongoing and will be presented by the study investigators at a future scientific conference in 2017.
    • 01 May 2017 Top-line results published in a Cerecor media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top